European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
From signals to phenotype: multifactorial drivers of tumor-associated macrophage polarization in oral cavity squamous cell carcinoma: a narrative review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamdan Ahmad Mohammad, El-Sehrawy Amr Ali Mohamed Abdelgawwad, Davlatova Aziza, Tailor Navin Kumar, Singh Ritesh, Tursunov Quvonch, Shakhmurova Gulnora
Аннотация
PURPOSE: This narrative review aimed to integrate oral cavity squamous cell carcinoma (OSCC)-specific evidence on the signals shaping the spatial and functional heterogeneity of tumor-associated macrophages (TAMs) and to evaluate their implications for tumor progression, treatment response, biomarker development, and therapeutic targeting.
METHODS: PubMed/MEDLINE, Scopus, and Web of Science were searched from database inception to July 15, 2026, for mechanistic, spatial, preclinical, translational, and clinical studies concerning TAM recruitment, polarization, tumor-macrophage crosstalk, biomarkers, and TAM-directed interventions in OSCC. Broader head and neck squamous cell carcinoma evidence was considered only when directly relevant OSCC-specific evidence was limited.
RESULTS: The available evidence supports a continuum model of macrophage activation rather than a rigid M1/M2 classification. Hypoxia, lactate accumulation, cytokine and chemokine signaling, cancer-associated fibroblasts, extracellular-matrix remodeling, extracellular vesicles, and oral microbial cues converge to generate heterogeneous TAM states. These states can promote immune suppression, angiogenesis, epithelial-mesenchymal plasticity, invasion, metastatic niche formation, and resistance to immunotherapy or radiochemotherapy. CD163- and CD206-enriched macrophage populations are frequently associated with adverse clinicopathologic features, whereas treatment-related changes in macrophage composition may provide exploratory response-associated or pharmacodynamic information. Preclinical studies further indicate that disrupting recruitment, survival, metabolic, microbial, or vesicle-mediated feedback circuits, or reprogramming suppressive TAMs, can reduce tumor-promoting activity.
CONCLUSION: TAMs should be evaluated as spatially organized, functionally diverse, and treatment-responsive populations. Clinically useful biomarkers and therapeutic approaches will require standardized, function-based characterization and prospective validation of rational combinations with immunotherapy and radiochemotherapy.
METHODS: PubMed/MEDLINE, Scopus, and Web of Science were searched from database inception to July 15, 2026, for mechanistic, spatial, preclinical, translational, and clinical studies concerning TAM recruitment, polarization, tumor-macrophage crosstalk, biomarkers, and TAM-directed interventions in OSCC. Broader head and neck squamous cell carcinoma evidence was considered only when directly relevant OSCC-specific evidence was limited.
RESULTS: The available evidence supports a continuum model of macrophage activation rather than a rigid M1/M2 classification. Hypoxia, lactate accumulation, cytokine and chemokine signaling, cancer-associated fibroblasts, extracellular-matrix remodeling, extracellular vesicles, and oral microbial cues converge to generate heterogeneous TAM states. These states can promote immune suppression, angiogenesis, epithelial-mesenchymal plasticity, invasion, metastatic niche formation, and resistance to immunotherapy or radiochemotherapy. CD163- and CD206-enriched macrophage populations are frequently associated with adverse clinicopathologic features, whereas treatment-related changes in macrophage composition may provide exploratory response-associated or pharmacodynamic information. Preclinical studies further indicate that disrupting recruitment, survival, metabolic, microbial, or vesicle-mediated feedback circuits, or reprogramming suppressive TAMs, can reduce tumor-promoting activity.
CONCLUSION: TAMs should be evaluated as spatially organized, functionally diverse, and treatment-responsive populations. Clinically useful biomarkers and therapeutic approaches will require standardized, function-based characterization and prospective validation of rational combinations with immunotherapy and radiochemotherapy.